期刊文献+

参芪扶正联合PG方案治疗晚期非小细胞肺癌的疗效观察 被引量:17

Efficacy of Shenqifuzheng injection combined PG therapy in treatment of non-small cell lung cancer
暂未订购
导出
摘要 目的观察参芪扶正注射液联合吉西他滨和顺铂(gemcitabine&cisplatin,PG)方案治疗非小细胞肺癌(non—small ceil lung cancer,NSCLC)的疗效。方法选择201 1年8月~201 3年8月在上海交通大学附属第六人民医院南院就诊的NSCLC 76例患者,随机分为观察组和对照组,每组38例。对照组予以吉西他滨和顺铂治疗,观察组在对照组的基础上予以参芪扶正注射液治疗。观察2组治疗后的总有效率、疾病控制率、生活质量和不良反应发生率。结果观察组的总有效率为47.37%,对照组的总有效率为42.11%,2组的总有效率差异无统计学意义,而观察组的疾病控制率为81.58%明显高于对照组的57.89%,差异有统计学意义(X^2=3.990,P<0.05)。观察组的生活质量改善率为60.53%明显优于对照组的31.58%,两组差异有统计学意义(X^245.296,P<0.05)。观察组的白细胞(X^2=4.491,P<0.05)和血小板(X^2=4.491,P<0.05)减少发生率明显低于对照组,而两组的肝功能损害和胃肠道反应差别无统计学意义。结论参芪扶正注射液有助于提高PG方案治疗NSCLC的疗效,并对化疗药物的毒副作用具有一定的缓解作用。 Objective To observe the shenqifuzheng injection (SFI) combined with PG therapy (gemcitabine and cisplatin) in patients with non-small cell lung cancer (NSCLC). Method 76 patients with NSCLC were selected from August 2011 to August 2013 and randomly divided into observation group and control group. Each group had 38 cases. The control group received gemcitabine and cisplatin, observation group were gave SFI on the basis of control group. The total efficiency, disease control rate, quality of life and incidence of adverse reactions were observed after treatment in each group. Results The total effective rate was 47.37%in observation group , 42.11%in control group, there was no significant difference between two groups. The disease control rate in observation group was 81.58%higher than 57.89%in control group, the difference was statistically significant (χ2=3.990, P<0.05). The improvement rate in quality of life was 60.53%in observation group better than 31.58%in the control group , the difference was statistically significant (χ2=5.296, P<0.05).The decrease incidence of white blood cell (χ2=4.491, P<0.05) and platelets (χ2=4.491, P<0.05) in observation group were significantly lower compared with the control group, while, there were no difference of liver damage and gastrointestinal reactions between two groups. Conclusion SFI is helpful to improve the efficacy of PG therapy in patients with NSCLC and relieve the side effects of chemotherapy.
出处 《中国生化药物杂志》 CAS 北大核心 2014年第1期88-89,92,共3页 Chinese Journal of Biochemical Pharmaceutics
关键词 参芪扶正注射液 吉西他滨 顺铂 非小细胞肺癌 化疗 Shenqifuzheng injection gemcitabine cisplatin non-small cell lung cancer chemotherapy
  • 相关文献

参考文献6

二级参考文献38

  • 1刘城林,陈为平,崔书中,邓广业,刘丽萍,覃丽红,苏旭春,闫冰川,孔嘉欣.参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J].中国中西医结合杂志,2004,24(10):901-903. 被引量:28
  • 2陈蕾,郑瑾,徐绮腻,杜彩文,郑毓武.4种化疗方案治疗非小细胞肺癌的临床研究[J].医师进修杂志,2005,28(2):34-35. 被引量:5
  • 3付玉兰,李辉贤,雷成阳,李涛,亣芳迎.参芪扶正注射液配合卵巢癌术后化疗临床观察[J].现代肿瘤医学,2005,13(1):110-111. 被引量:5
  • 4魏宇宁,傅宏义,辛海莉.非小细胞肺癌四种化疗方案成本-效果分析[J].中国全科医学,2005,8(9):752-753. 被引量:7
  • 5姚志华,张明智.中药抗恶性肿瘤研究进展[J].现代肿瘤医学,2006,14(4):503-505. 被引量:60
  • 6Granville CA,Dennis PA.An overview of lung cancer genomics and proteomics[J].Am J Respir Cell Mol Biol,2005,32(3):169-176.
  • 7Socinski MA,Morris DE,Masters GA,et al.Chemotherapeutic management of stage Ⅳ non-small cell lung cancer[J].Chest,2003,123 (I Supp l):226 s-243 s.
  • 8贺用和 林洪生.中药与化疗结合治疗癌症的进展.中华新医学,2002,3(4):355-357.
  • 9Masafumi Ikeda,Yasuaki Arai,Sang Joon Park,Yoshito Takeuchi,Hiroshi Anai,Jae Kyu Kim,Yoshitaka Inaba,Takeshi Aramaki,Se Hwan Kwon,Seiichiro Yamamoto,Takuji Okusaka.Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea[J]. Journal of Vascular and Interventional Radiology . 2013 (4)
  • 10Lu Wu,Ye-Fa Yang,Nai-Jian Ge,Shu-Qun Shen,Jun Liang,Yi Wang,Wei-Ping Zhou,Feng Shen,Meng-Chao Wu.Hepatic artery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study[J]. European Journal of Nuclear Medicine and Molecular Imaging . 2012 (8)

共引文献89

同被引文献163

引证文献17

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部